David R. Wise, MD, PhD, discusses the use of gotistobart, a next-generation CTLA-4 targeting antibody, in prostate cancer.
David R. Wise, MD, PhD
Articles by David R. Wise, MD, PhD
David R. Wise, MD, PhD, discusses the use of gotistobart, a next-generation CTLA-4 targeting antibody, in prostate cancer.
